The emerging role of PET in Hodgkin lymphoma patients receiving autologous stem cell transplant

Expert Review of Hematology

Volumn 5, Issue 5, 2012, Pages 483-486

  Von Tresckow, Bastian ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

autologous stem cell transplant; high dose chemotherapy; Hodgkin lymphoma; maintenance; PET; risk factors; tandem transplant

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; NAVELBINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CHEMOTHERAPY; EVENT FREE SURVIVAL; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84869151861     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.41     Document Type: Article

References (20)

1. Cocorocchio E, Peccatori F, Vanazzi A et al. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: A reappraisal of prognostic factors. Hematol. Oncol. doi:10.1002/hon.2014 (2012) (Epub ahead of print).
2. Martinelli G, Cocorocchio E, Peccatori F et al. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: A retrospective analysis. Br. J. Haematol. 125(5), 584-589 (2004).
3. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N. Engl. J. Med. 327(21), 1478-1484 (1992).
4. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J. Clin. Oncol. 22(14), 2835-2841 (2004).
5. Martinelli G, Cocorocchio E, Saletti PC et al. Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients. Leuk. Lymphoma 44(11), 1919-1923 (2003).
6. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 17(4), 1244 (1999).
7. Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fluoro-2-deoxy-dglucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J. Clin. Oncol. 25(24), 3746-3752 (2007).
8. Josting A, Franklin J, May M et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J. Clin. Oncol. 20(1), 221-230 (2002).
9. von Tresckow B, Engert A. The role of autologous transplantation in Hodgkin lymphoma. Curr. Hematol. Malig. Rep. 6(3), 172-179 (2011).
10. Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 97(3), 616-623 (2001).
11. Kobe C, Dietlein M, Franklin J et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112(10), 3989-3994 (2008).
12. Jabbour E, Hosing C, Ayers G et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/ refractory Hodgkin lymphoma. Cancer 109(12), 2481-2489 (2007).
13. Moskowitz AJ, Yahalom J, Kewalramani T et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 116(23), 4934-4937 (2010).
14. Castagna L, Bramanti S, Balzarotti M et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br. J. Haematol. 145(3), 369-372 (2009).
15. Schot BW, Zijlstra JM, Sluiter WJ et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 109(2), 486-491 (2007).
16. Mocikova H, Pytlik R, Markova J et al. Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. Leuk. Lymphoma 52(9), 1668-1674 (2011).
17. Sucak GT, Özkurt ZN, Suyani E et al. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann. Hematol. 90(11), 1329-1336 (2011).
18. Palmer J, Goggins T, Broadwater G et al. Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant. 46(6), 847-851 (2011).
19. Devillier R, Coso D, Castagna L et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica 97(7), 1073-1079 (2012).
20. Moskowitz CH, Matasar MJ, Zelenetz AD et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119(7), 1665-1670 (2012).21 Younes A, Gopal AK, Smith SE et al. Results of a pivotal Phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 30(18), 2183-2189 (2012).